Celsion
About
Celsion is a biopharmaceutical company which develops innovative, targeted therapies that address unmet medical needs in oncology.
- 11 - 50
Highlights
Details
- Last Funding Type
- Post-IPO Debt
- Last Funding Money Raised
- $20M
- Industries
- Biotechnology,Health Care,Therapeutics
- Founded date
- Jan 1, 1982
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Celsion is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative cancer treatments, including immunotherapies and DNA-based therapies; and a platform for the development of nucleic acid vaccines currently focused on SARS-CoV2. The company’s product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer. ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, is under investigator-sponsored development for several cancer indications. Celsion also has two feasibility stage platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Nov 26, 2013 | Post-IPO Debt | $20M | 1 |
Hercules Capital
|
— | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Hercules Capital
|
Yes | Post-IPO Debt |
